Larry Ramer

Larry Ramer

InvestorPlace Contributor

Larry Ramer has more than 15 years of experience in business journalism. He has worked for Globes, Israel’s most widely read business newspaper, as well as The Jerusalem Post and theflyonthewall.

Mr. Ramer’s expansive knowledge of politics enables him to provide valuable insights into how politics can affect stocks. He also focuses on contrary investing and specializes in the renewable energy and consumer discretionary sectors.

Among his highly successful, contrarian picks have been Super Micro Computer, Intel, and MGM Resorts.

You can reach him on StockTwits at @larryramer and learn more about his stock-picking record at his TipRanks profile.

Recent Articles

Enphase Is a Great Company, But ENPH Stock Is Not a Great Pick

By Larry Ramer, InvestorPlace Contributor

Other solar stocks are more likely to outperform than ENPH stock, whose valuation may scare away many investors. Try one of these instead.

ContextLogic Can Still Rebound, but Don’t Buy WISH Stock Just Yet

By Larry Ramer, InvestorPlace Contributor

ContextLogic continues to undertake very good strategies, and WISH stock may become a buy in the second half of the year.

Upstart’s Outlook Has Brightened with Long-Term Opportunities

By Larry Ramer, InvestorPlace Contributor

An improving macro picture as well as new endeavors should boost Upstart and UPST stock in 2022. The stock is a buy for growth investors.

Some Investors Should Buy Novavax Stock on the Dip

By Larry Ramer, InvestorPlace Contributor

Novavax remains poised to sell its coronavirus vaccine to many countries around the world, giving NVAX stock a strong revenue stream in 2022.

The Market Is Greatly Underestimating C3.ai Stock

By Larry Ramer, InvestorPlace Contributor

C3.ai has important advantages over its competitors and has recruited superb partners, while the valuation of AI stock is reasonable.

XERS Stock Pops on Huge FDA News. Here’s What to Know.

By Larry Ramer, InvestorPlace Contributor

The FDA approved Xeris' Recorlev drug for certain adult patients with Cushing's syndrome, sending XERS stock higher.

NTRB Stock Alert: The Patent News Sending Nutriband Soaring

By Larry Ramer, InvestorPlace Contributor

NTRB stock has more than doubled after Nutriband received a patent from South Korea for its transdermal patch tech.

Meta’s Threats Could Catch Up to It in 2022

By Larry Ramer, InvestorPlace Contributor

With Meta's ad business contending with key challenges and the company dealing with many other threats, investors may want to avoid FB stock.

EVgo Stock Looks Even More Attractive Following Sell-off

By Larry Ramer, InvestorPlace Contributor

EVGO stock is a steal following a 20% drop in recent weeks, as the company looks to expand its charging station network.

IMTE Stock: The NFT Trading Platform Plans Sending Integrated Media Technology Soaring Today

By Larry Ramer, InvestorPlace Contributor

Under a new agreement, Integrated Media, which specializes in 3D technology, will take over an NFT platform. Today, IMTE stock is rallying.

Load More